The development of treatments for rare diseases are slowed by a number of challenges.  In this article, from Genetic Engineering and Biotechnology News, our President and CEO, Patti Engel, shares ways that these timelines may be shortened, and highlights ongoing research that may provide practical insights to drug developers.